Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 13/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26675388 | 1.00 | GBA1 (0.49) | GBA1ATML3MBTL1ALDH1A1MAPT | |
| SCHEMBL26675390 | 0.87 | SMN1; SMN2 (0.52) | GBA1L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29767973 | 0.87 | SMN1; SMN2 (0.52) | GBA1L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30600514 | 0.86 | GBA1 (0.42) | GBA1ALDH1A1MAPTSMN1; SMN2ENPP3 | |
| SCHEMBL26675357 | 0.86 | GBA1 (0.42) | GBA1ALDH1A1MAPTSMN1; SMN2ENPP3 | |
| SCHEMBL26675414 | 0.86 | HSD17B10 (0.47) | ALDH1A1MAPTSMN1; SMN2HTTTP53 | |
| SCHEMBL29767967 | 0.86 | HSD17B10 (0.47) | ALDH1A1MAPTSMN1; SMN2HTTTP53 | |
| SCHEMBL29767955 | 0.84 | HSD17B10 (0.47) | ALDH1A1MAPTSMN1; SMN2HTTTP53 | |
| SCHEMBL26675397 | 0.84 | HSD17B10 (0.47) | ALDH1A1MAPTSMN1; SMN2HTTTP53 | |
| SCHEMBL29767966 | 0.83 | GBA1 (0.55) | GBA1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284797-A1 | PYRAZOLEAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-12-06 | — | — | EP | claimed |
| CN-116867782-A | Pyrazole amide derivative | 豪夫迈·罗氏有限公司 | 2023-10-10 | — | — | CN | claimed |
| WO-2022162034-A1 | PYRAZOLEAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-04 | — | — | WO | claimed |
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4284797-A1 | PYRAZOLEAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| CN-116867782-A | Pyrazole amide derivative | 豪夫迈·罗氏有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022162034-A1 | PYRAZOLEAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | GBA1 510/4885ATM 3197/4885L3MBTL1 4647/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | GBA1 2014/4885ATM 1826/4885L3MBTL1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.